Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Work
Year: 2015
Type: article
Abstract: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating ... more
Source: Journal of Clinical Oncology
Authors Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Thomas Amatruda, Neil Senzer +24 more
Institutions Huntsman Cancer Institute, Minnesota Oncology, Mary Crowley Cancer Research Center, Amgen (United States)
Cites: 71
Cited by: 2,264
Related to: 10
FWCI: 111.6
Citation percentile (by year/subfield): 100
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze